Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,434,993 papers from all fields of science
Search
Sign In
Create Free Account
iganidipine
Known as:
3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Piperazines
Pyridines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Nuevos desarrollos en el tratamiento médico del glaucoma
F. Muñoz-Negrete
,
M. Pérez-López
,
H.-R. Won Kim
,
G. Rebolleda
2009
Corpus ID: 48086773
espanolEl tratamiento medico del glaucoma ha presentado una gran evolucion en los ultimos anos. Las investigaciones que se estan…
Expand
Review
2009
Review
2009
[New developments in glaucoma medical treatment].
F. Muñoz-Negrete
,
M. Pérez-López
,
H. W. Won Kim
,
G. Rebolleda
Archivos de la Sociedad Española de Oftalmología
2009
Corpus ID: 25466280
The medical treatment of glaucoma has undergone significant development in recent years. Research in this field is focused on…
Expand
2005
2005
Ocular Distribution After Topical Instillation and Potential Neuroprotective Effect After Intravitreal Injection of the Calcium Channel Blocker Iganipidine
M. Ohashi
,
Shinichiro Saito
,
+4 authors
Yasuyuki Suzuki
Current Eye Research
2005
Corpus ID: 29241751
Purpose: To investigate the effects of iganidipine, a new calcium antagonist on glutamate agonist–induced retinal damage. Methods…
Expand
2004
2004
Topical administration of iganidipine, a new water-soluble ca2+ antagonist, increases ipsilateral optic nerve head circulation in rabbits and cynomolgus monkeys
K. Ishii
,
Y. Fukaya
,
M. Araie
,
G. Tomita
Current Eye Research
2004
Corpus ID: 43471414
Purpose. To evaluate the effects of topically administered iganidipine hydrochloride, a novel water-soluble Ca2+-channel blocker…
Expand
2003
2003
Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation.
K. Ishii
,
H. Matsuo
,
+4 authors
M. Araie
Investigative Ophthalmology and Visual Science
2003
Corpus ID: 37863160
PURPOSE To evaluate the potential of topical iganidipine ophthalmic solution to exert Ca(2+)-antagonistic activity in the…
Expand
2002
2002
Effect of Topical Iganidipine on Experimental Elevation of Aqueous Flare Induced by Prostaglandin E2 and EP Agonists in Pigmented Rabbits
S. Yanagisawa
,
S. Hayasaka
,
Xue-Yun Zhang
,
Y. Hayasaka
,
Y. Nagaki
Ophthalmic Research
2002
Corpus ID: 19657941
We evaluated the role of topical iganidipine on experimental aqueous flare elevation in rabbits. Transcorneal diffusion of…
Expand
2001
2001
Effect of topically applied iganidipine dihydrochloride, a novel calcium antagonist, on optic nerve head circulation in rabbits.
M. Waki
,
T. Sugiyama
,
N. Watanabe
,
T. Ogawa
,
H. Shirahase
,
I. Azuma
Japanese Journal of Ophthalmology
2001
Corpus ID: 41128069
PURPOSE To study the effect of topically applied iganidipine dihydrochloride (iganidipine), a novel water-soluble calcium channel…
Expand
2000
2000
Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits.
H. Oku
,
T. Sugiyama
,
S. Kojima
,
T. Watanabe
,
T. Ikeda
Current Eye Research
2000
Corpus ID: 44751365
PURPOSE To investigate the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker, on impairment…
Expand
2000
2000
[Effect of topically applied iganidipine dihydrochloride, a novel Ca2+ antagonist, on optic nerve head circulation in rabbits].
M. Waki
,
T. Sugiyama
,
N. Watanabe
,
T. Ogawa
,
H. Shirahase
,
I. Azuma
Nippon Ganka Gakkai zasshi
2000
Corpus ID: 33828397
1996
1996
Pharmacodynamics and pharmacokinetics of iganidipine
S. Yamada
,
R. Kimura
1996
Corpus ID: 73058301
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE